Takakubo Yuya, Konttinen Yrjö T
Department of Medicine, Biomedicum Helsinki, University of Helsinki, PO Box 700, Haartmaninkatu 8, 00029 HUS, Finland.
Clin Dev Immunol. 2012;2012:941346. doi: 10.1155/2012/941346. Epub 2011 Oct 27.
Systemic autoimmune and rheumatic diseases (SAIRDs) are thought to develop due to the failure of autoimmune regulation and tolerance. Current therapies, such as biologics, have improved the clinical results of SAIRDs; however, they are not curative treatments. Recently, new discoveries have been made in immune tolerance and inflammation, such as tolerogenic dendritic cells, regulatory T and B cells, Th 17 cells, inflammatory and tolerogenic cytokines, and intracellular signaling pathways. They lay the foundation for the next generation of the therapies beyond the currently used biologic therapies. New drugs should target the core processes involved in disease mechanisms with the aim to attain complete cure combined with safety and low costs compared to the biologic agents. Re-establishment of autoimmune regulation and tolerance in SAIRDs by the end of the current decade should be the final and realistic target.
系统性自身免疫性和风湿性疾病（SAIRDs）被认为是由于自身免疫调节和耐受功能失效而发展起来的。目前的治疗方法，如生物制剂，已经改善了SAIRDs的临床疗效；然而，它们并非治愈性疗法。最近，在免疫耐受和炎症方面有了新的发现，比如耐受性树突状细胞、调节性T细胞和B细胞、Th17细胞、炎性和耐受性细胞因子以及细胞内信号通路。它们为下一代超越当前使用的生物治疗的疗法奠定了基础。新药应以疾病机制中涉及的核心过程为靶点，目标是与生物制剂相比，在确保安全和低成本的同时实现完全治愈。在本十年末通过重新建立SAIRDs中的自身免疫调节和耐受应成为最终且现实的目标。
